Ulevostinag
Head and Neck Squamous Cell Carcinoma (HNSCC)
Merck Sharp & Dohme LLCSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 81/ 100
Competitive context
250 Active assets in the Head and Neck Squamous Cell Carcinoma (HNSCC) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CIS-DIAMMINEDICHLOROPLATINUM II Akeso | Phase 3 | BB |
Carboplatin Akeso | Phase 4 | BB |
Irinotecan Neonc Technologies, Inc. | Phase 2 | BB |
Capecitabine Merck Sharp & Dohme LLC | Phase 2 | BB |
Tisotumab Vedotin Seagen, a wholly owned subsidiary of Pfizer | Phase 2 | BB |
View all 50 →
Same molecule, other indications
Ulevostinag is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →